REQUEST A DEMO
Total
USD $0.00
Search more companies

Samsung Bioepis Co,.Ltd. (Incheon) (South Korea)

Main Activities: Scientific Research and Development Services
Full name: Samsung Bioepis Co,.Ltd. Profile Updated: October 23, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Samsungbioepis Co,.Ltd is a biopharmaceutical company that specializes in the development and marketing of biosimilars for the treatment of various diseases, including rheumatoid arthritis, psoriasis, and other immunological conditions. Samsungbioepis Co,.Ltd aims to increase patient access to medicines and is focused on becoming a leading biopharmaceutical company with a heritage of innovation and advanced technologies. The company offers BENEPALI, a biosimilar referencing ENBREL, approved for the treatment of various conditions, including rheumatoid arthritis and psoriasis.

Headquarters
76, Songdogyoyuk-ro Yeonsu-gu Incheon
Incheon; Incheon; Postal Code: 406840

Contact Details: Purchase the Samsung Bioepis Co,.Ltd. (Incheon) report to view the information.

Website: http://www.samsungbioepis.com

Basic Information
Total Employees:
Purchase the Samsung Bioepis Co,.Ltd. (Incheon) report to view the information.
Outstanding Shares:
Purchase the Samsung Bioepis Co,.Ltd. (Incheon) report to view the information.
Registered Capital:
Purchase the Samsung Bioepis Co,.Ltd. (Incheon) report to view the information.
Incorporation Date:
February 28, 2012
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Subsidiaries
S1crm
Samsung C&T Corporation
Samsung Sdi Co.,Ltd.
Company Performance
Financial values in the chart are available after Samsung Bioepis Co,.Ltd. (Incheon) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
11.27%
Total operating revenue
11.27%
Operating profit (EBIT)
19.07%
EBITDA
6.87%
Net Profit (Loss) for the Period
44.97%
Total assets
1.68%
Total equity
22.79%
Operating Profit Margin (ROS)
1.58%
Net Profit Margin
5.34%
Return on Equity (ROE)
2.82%
Debt to Equity Ratio
-3.87%
Quick Ratio
0.07%
Cash Ratio
0.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?